Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment…
Abivertinib is a novel Bruton’s tyrosine kinase (BTK) inhibitor that irreversibly targets BTK. BTK inhibitors are a large category in cancer treatment, with multiple indications and…